Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279641 · ClinicalTrials.gov registry record · Phase 1
RDEA3170 and Allopurinol Combination Study in Gout Subjects
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02279641: Completed Phase 1 study, sponsored by Ardea Biosciences.
NCT02279641 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02279641, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.
Primary Outcome
Cmax of Allopurinol/Oxypurinol Alone and In Combination with RDEA3170
Interventions
- DRUG allopurinol 300 mg
- DRUG RDEA3170 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-11-01 |
| Est. Completion | 2015-09-11 |
| Phase | Phase 1 |
What the finished NCT02279641 record still lists
NCT02279641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which allopurinol 300 mg is the first listed.
NCT02279641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02279641 about?
NCT02279641 is a clinical study titled "RDEA3170 and Allopurinol Combination Study in Gout Subjects". This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.
What is the current status of trial NCT02279641?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-11-01. Estimated completion is 2015-09-11.
What interventions are being tested in trial NCT02279641?
The interventions under investigation include: allopurinol 300 mg (DRUG), RDEA3170 10 mg (DRUG).
Who is sponsoring clinical trial NCT02279641?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02279641's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI